{"success":true,"data":{"pressRelease":{"id":"157257","rtpr_id":"nPn7W9VdSa-20260930","ticker":"HALO","exchange":"NASDAQ","all_tickers":["HALO"],"title":"Halozyme Announces Appointment of Jim Daly to its Board of Directors","author":"PR Newswire","published_at":"2026-09-30T20:05:01.437Z","article_body":"Halozyme Announces Appointment of Jim Daly to its Board of Directors\nPR Newswire\n\nSAN DIEGO, Sept. 30, 2026\n\nSAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq:\nHALO) (\"Halozyme\" or the \"Company\") today announced the appointment of James\n\"Jim\" Daly to its Board of Directors. Mr. Daly is a highly respected\nbiopharmaceutical executive with more than three decades of commercial\nleadership experience and a proven track record of shaping the profile of\ninnovative therapies resulting in highly successful launches of respiratory,\noncology and immunology therapies.\n\n\"We are delighted to welcome Jim back to Halozyme's Board of Directors,\" said\nDr. Helen Torley, President and Chief Executive Officer of Halozyme. \"Jim\nbrings exceptional industry knowledge, commercial expertise, strategic\ninsight, and governance experience. His extensive background leading the\nlaunches and growth of multiple blockbuster therapies will be invaluable as\nHalozyme continues to expand the number of products using our subcutaneous\n(SC) delivery technologies, ENHANZE, and our two hyperconcentration\ntechnologies, Hypercon and Aerocon.\"\n\nMr. Daly previously served on Halozyme's Board of Directors and has held\nsenior commercial leadership roles across leading global biopharmaceutical\ncompanies.\n\nHe served as Executive Vice President and Chief Commercial Officer of Incyte\nCorporation from 2012 to 2015. Prior to Incyte, he spent a decade at Amgen,\nwhere he held senior commercial leadership positions, including his most\nrecent role as Senior Vice President, North America Commercial Operations,\nGlobal Marketing and Commercial Development. Earlier in his career, Mr. Daly\nspent more than 16 years at Glaxo Wellcome/GlaxoSmithKline, where he held\npositions of increasing responsibility, including Senior Vice President and\nGeneral Manager of the U.S. respiratory business.\n\n\"I am pleased to rejoin Halozyme's Board at such an exciting time in the\ncompany's evolution,\" said Mr. Daly. \"Halozyme has created an impressive\nportfolio of SC delivery technologies, with ENHANZE the clear gold standard in\nterms of large volume SC delivery, and Hypercon and Aerocon leading the way to\nenabling more at home delivery of biologic medicines. I am excited to work\nwith the management team and the Board to continue to transform the patient\ntreatment experience and potentially outcomes.\"\n\nMr. Daly currently serves on the boards of Acadia Pharmaceuticals, Madrigal\nPharmaceuticals and Cytokinetics. He previously served on the boards of\nargenx, Bellicum Pharmaceuticals and Chimerix.\n\nHe holds a Bachelor of Science in Pharmacy and an M.B.A. from the University\nat Buffalo, State University of New York.\n\nAbout Halozyme\n\nHalozyme is a biopharmaceutical company advancing disruptive solutions to\nimprove patient experiences and outcomes for emerging and established\ntherapies. As the innovators of ENHANZE(®) drug delivery technology with the\nproprietary enzyme rHuPH20, Halozyme's commercially-validated solution\nfacilitates the subcutaneous delivery of injected drugs and fluids, reducing\ntreatment burden and improving convenience. ENHANZE(®) has touched more than\none million patient lives through ten commercialized products across over 100\nglobal markets and is licensed to leading pharmaceutical and biotechnology\ncompanies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly,\nBristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen\nPharmaceuticals, Merus N.V., GSK, and Incyte.\n\nHalozyme expanded its drug delivery technology portfolio to develop partner\nproducts using Hypercon™ and Surf Bio's hyperconcentration technology,\nrecently renamed as Aerocon™. Hypercon™ is an innovative microparticle\ntechnology expected to set a new standard in hyperconcentration of drugs and\nbiologics by reducing injection volume for the same dosage and enabling\nadministration in at‑home and healthcare‑provider settings. Aerocon's\npolymer‑based hyperconcentration technology further broadens the range of\nbiologics that can be delivered subcutaneously, meaningfully expanding the\nscope of opportunities across therapeutic modalities. Together, Hypercon™\nand Aerocon™ complement ENHANZE(®) by enabling creation and delivery of\nhighly concentrated biologics. The Hypercon™ technology has been licensed to\nleading biopharmaceutical partners, including Janssen, Eli Lilly, argenx,\nVertex Pharmaceuticals and Oruka Therapeutics.\n\nHalozyme also develops, manufactures and commercializes drug-device\ncombination products using advanced auto-injector technologies designed to\nimprove convenience, reliability and tolerability, enhancing patient comfort\nand adherence. The Company has two proprietary commercial products, Hylenex(®\n)and XYOSTED(®), partnered commercial products and ongoing development\nprograms with Teva Pharmaceuticals and McDermott Laboratories Limited, an\naffiliate of Viatris Inc.\n\nHalozyme is headquartered in San Diego, CA, with offices in Ewing, NJ;\nMinnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations\nfacility.\n\nFor more information, visit www.halozyme.com (http://www.halozyme.com) and\nconnect with us on LinkedIn.\n\nSafe Harbor Statement\n\nThis press release may include forward-looking statements as defined in the\nPrivate Securities Litigation Reform Act of 1995, as amended. Forward-looking\nstatements are statements that are not historical facts and may include\nprojections and estimates and their underlying assumptions, statements\nregarding plans, objectives, intentions and expectations with respect to\nfuture financial results, events, operations, services, product development\nand potential and statements regarding future performance and growth of\nHalozyme's business. Forward-looking statements are generally identified by\nthe words \"expects\", \"anticipates\", \"believes\", \"intends\", \"estimates\",\n\"plans\", \"will be\" and similar expressions. Although Halozyme believes that\nthe expectations reflected in such forward-looking statements are reasonable,\ninvestors are cautioned that forward-looking information and statements are\nsubject to various risks and uncertainties, many of which are difficult to\npredict and generally beyond the control of Halozyme, that could cause actual\nresults and developments to differ materially from those expressed in the\nforward-looking information and statements. Actual results could differ\nmaterially from the expectations contained in these forward-looking statements\nas a result of several factors. These and other factors that may result in\ndifferences are discussed in greater detail in the Company's most recently\nfiled Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with\nthe Securities and Exchange Commission. Halozyme undertakes no obligation to\nupdate or revise any forward-looking statements or any other information\ncontained herein.\n\nContact:\n\nTram Bui\nVP, Investor Relations and Corporate Communications\n609-333-7668\ntbui@halozyme.com (mailto:tbui@halozyme.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/halozyme-announces-appointment-of-jim-daly-to-its-board-of-directors-302893932.html\n(https://www.prnewswire.com/news-releases/halozyme-announces-appointment-of-jim-daly-to-its-board-of-directors-302893932.html)\n\nSOURCE Halozyme Therapeutics, Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS254664/Halozyme-Therapeutics-Logo.jpg?id=OA2978043\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn7W9VdSa-20260930","title":"Halozyme Announces Appointment of Jim Daly to its Board of Directors","author":"PR Newswire","ticker":"HALO","created":"2026-09-30T20:05:01.437Z","tickers":["HALO"],"exchange":"NASDAQ","article_body":"Halozyme Announces Appointment of Jim Daly to its Board of Directors\nPR Newswire\n\nSAN DIEGO, Sept. 30, 2026\n\nSAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq:\nHALO) (\"Halozyme\" or the \"Company\") today announced the appointment of James\n\"Jim\" Daly to its Board of Directors. Mr. Daly is a highly respected\nbiopharmaceutical executive with more than three decades of commercial\nleadership experience and a proven track record of shaping the profile of\ninnovative therapies resulting in highly successful launches of respiratory,\noncology and immunology therapies.\n\n\"We are delighted to welcome Jim back to Halozyme's Board of Directors,\" said\nDr. Helen Torley, President and Chief Executive Officer of Halozyme. \"Jim\nbrings exceptional industry knowledge, commercial expertise, strategic\ninsight, and governance experience. His extensive background leading the\nlaunches and growth of multiple blockbuster therapies will be invaluable as\nHalozyme continues to expand the number of products using our subcutaneous\n(SC) delivery technologies, ENHANZE, and our two hyperconcentration\ntechnologies, Hypercon and Aerocon.\"\n\nMr. Daly previously served on Halozyme's Board of Directors and has held\nsenior commercial leadership roles across leading global biopharmaceutical\ncompanies.\n\nHe served as Executive Vice President and Chief Commercial Officer of Incyte\nCorporation from 2012 to 2015. Prior to Incyte, he spent a decade at Amgen,\nwhere he held senior commercial leadership positions, including his most\nrecent role as Senior Vice President, North America Commercial Operations,\nGlobal Marketing and Commercial Development. Earlier in his career, Mr. Daly\nspent more than 16 years at Glaxo Wellcome/GlaxoSmithKline, where he held\npositions of increasing responsibility, including Senior Vice President and\nGeneral Manager of the U.S. respiratory business.\n\n\"I am pleased to rejoin Halozyme's Board at such an exciting time in the\ncompany's evolution,\" said Mr. Daly. \"Halozyme has created an impressive\nportfolio of SC delivery technologies, with ENHANZE the clear gold standard in\nterms of large volume SC delivery, and Hypercon and Aerocon leading the way to\nenabling more at home delivery of biologic medicines. I am excited to work\nwith the management team and the Board to continue to transform the patient\ntreatment experience and potentially outcomes.\"\n\nMr. Daly currently serves on the boards of Acadia Pharmaceuticals, Madrigal\nPharmaceuticals and Cytokinetics. He previously served on the boards of\nargenx, Bellicum Pharmaceuticals and Chimerix.\n\nHe holds a Bachelor of Science in Pharmacy and an M.B.A. from the University\nat Buffalo, State University of New York.\n\nAbout Halozyme\n\nHalozyme is a biopharmaceutical company advancing disruptive solutions to\nimprove patient experiences and outcomes for emerging and established\ntherapies. As the innovators of ENHANZE(®) drug delivery technology with the\nproprietary enzyme rHuPH20, Halozyme's commercially-validated solution\nfacilitates the subcutaneous delivery of injected drugs and fluids, reducing\ntreatment burden and improving convenience. ENHANZE(®) has touched more than\none million patient lives through ten commercialized products across over 100\nglobal markets and is licensed to leading pharmaceutical and biotechnology\ncompanies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly,\nBristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen\nPharmaceuticals, Merus N.V., GSK, and Incyte.\n\nHalozyme expanded its drug delivery technology portfolio to develop partner\nproducts using Hypercon™ and Surf Bio's hyperconcentration technology,\nrecently renamed as Aerocon™. Hypercon™ is an innovative microparticle\ntechnology expected to set a new standard in hyperconcentration of drugs and\nbiologics by reducing injection volume for the same dosage and enabling\nadministration in at‑home and healthcare‑provider settings. Aerocon's\npolymer‑based hyperconcentration technology further broadens the range of\nbiologics that can be delivered subcutaneously, meaningfully expanding the\nscope of opportunities across therapeutic modalities. Together, Hypercon™\nand Aerocon™ complement ENHANZE(®) by enabling creation and delivery of\nhighly concentrated biologics. The Hypercon™ technology has been licensed to\nleading biopharmaceutical partners, including Janssen, Eli Lilly, argenx,\nVertex Pharmaceuticals and Oruka Therapeutics.\n\nHalozyme also develops, manufactures and commercializes drug-device\ncombination products using advanced auto-injector technologies designed to\nimprove convenience, reliability and tolerability, enhancing patient comfort\nand adherence. The Company has two proprietary commercial products, Hylenex(®\n)and XYOSTED(®), partnered commercial products and ongoing development\nprograms with Teva Pharmaceuticals and McDermott Laboratories Limited, an\naffiliate of Viatris Inc.\n\nHalozyme is headquartered in San Diego, CA, with offices in Ewing, NJ;\nMinnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations\nfacility.\n\nFor more information, visit www.halozyme.com (http://www.halozyme.com) and\nconnect with us on LinkedIn.\n\nSafe Harbor Statement\n\nThis press release may include forward-looking statements as defined in the\nPrivate Securities Litigation Reform Act of 1995, as amended. Forward-looking\nstatements are statements that are not historical facts and may include\nprojections and estimates and their underlying assumptions, statements\nregarding plans, objectives, intentions and expectations with respect to\nfuture financial results, events, operations, services, product development\nand potential and statements regarding future performance and growth of\nHalozyme's business. Forward-looking statements are generally identified by\nthe words \"expects\", \"anticipates\", \"believes\", \"intends\", \"estimates\",\n\"plans\", \"will be\" and similar expressions. Although Halozyme believes that\nthe expectations reflected in such forward-looking statements are reasonable,\ninvestors are cautioned that forward-looking information and statements are\nsubject to various risks and uncertainties, many of which are difficult to\npredict and generally beyond the control of Halozyme, that could cause actual\nresults and developments to differ materially from those expressed in the\nforward-looking information and statements. Actual results could differ\nmaterially from the expectations contained in these forward-looking statements\nas a result of several factors. These and other factors that may result in\ndifferences are discussed in greater detail in the Company's most recently\nfiled Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with\nthe Securities and Exchange Commission. Halozyme undertakes no obligation to\nupdate or revise any forward-looking statements or any other information\ncontained herein.\n\nContact:\n\nTram Bui\nVP, Investor Relations and Corporate Communications\n609-333-7668\ntbui@halozyme.com (mailto:tbui@halozyme.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/halozyme-announces-appointment-of-jim-daly-to-its-board-of-directors-302893932.html\n(https://www.prnewswire.com/news-releases/halozyme-announces-appointment-of-jim-daly-to-its-board-of-directors-302893932.html)\n\nSOURCE Halozyme Therapeutics, Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS254664/Halozyme-Therapeutics-Logo.jpg?id=OA2978043\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-30T20:05:01.479610659Z","server_sent_at_ms":1790798701479},"received_at":"2026-09-30T20:05:01.530Z","source_url":"https://www.prnewswire.com/news-releases/halozyme-announces-appointment-of-jim-daly-to-its-board-of-directors-302893932.html"},"analysis":{"id":"145923","press_release_id":"157257","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"board_change","narrative":"Halozyme Therapeutics appointed James \"Jim\" Daly to its Board of Directors, a biopharma commercial executive with over three decades of experience.\n\nDaly previously served on Halozyme's board and held senior commercial roles at Incyte, Amgen, and GlaxoSmithKline; he currently sits on the boards of Acadia, Madrigal, and Cytokinetics.\n\nThe appointment is a routine governance update with no change to strategy or management, though Daly's commercial launch experience supports Halozyme's expanding ENHANZE, Hypercon, and Aerocon partnerships.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine board refreshment -- returning director with deep commercial launch experience."},"keyFigures":{},"quotedText":"Jim brings exceptional industry knowledge, commercial expertise, strategic insight, and governance experience.","namedEntities":{"people":[{"name":"James \"Jim\" Daly","role":"Board of Directors member (incoming)"},{"name":"Dr. Helen Torley","role":"President and CEO"}],"products":["ENHANZE","Hypercon","Aerocon","Hylenex","XYOSTED"],"companies":[{"name":"Halozyme Therapeutics, Inc.","ticker":"HALO","relationship":"filer"},{"name":"Incyte Corporation","relationship":"Daly's former employer"},{"name":"Amgen","relationship":"Daly's former employer"},{"name":"Glaxo Wellcome/GlaxoSmithKline","relationship":"Daly's former employer"},{"name":"Acadia Pharmaceuticals","relationship":"Daly's current board seat"},{"name":"Madrigal Pharmaceuticals","relationship":"Daly's current board seat"},{"name":"Cytokinetics","relationship":"Daly's current board seat"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine board appointment of a returning former director with strong industry background. No change in strategy, leadership of management, or financial profile."},"tickerRelevance":{"others":[],"primary":"HALO"},"globalImportance":12,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap biotech","eventGravity":"routine-board-appointment","issuerAuthored":true,"householdBrandBoost":"moderate (mid-cap biotech with named pharma partners)"}},"event_type":"board_change","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Halozyme Therapeutics appointed James \"Jim\" Daly to its Board of Directors, a biopharma commercial executive with over three decades of experience.\n\nDaly previously served on Halozyme's board and held senior commercial roles at Incyte, Amgen, and GlaxoSmithKline; he currently sits on the boards of Acadia, Madrigal, and Cytokinetics.\n\nThe appointment is a routine governance update with no change to strategy or management, though Daly's commercial launch experience supports Halozyme's expanding ENHANZE, Hypercon, and Aerocon partnerships.","key_figures":{},"named_entities":{"people":[{"name":"James \"Jim\" Daly","role":"Board of Directors member (incoming)"},{"name":"Dr. Helen Torley","role":"President and CEO"}],"products":["ENHANZE","Hypercon","Aerocon","Hylenex","XYOSTED"],"companies":[{"name":"Halozyme Therapeutics, Inc.","ticker":"HALO","relationship":"filer"},{"name":"Incyte Corporation","relationship":"Daly's former employer"},{"name":"Amgen","relationship":"Daly's former employer"},{"name":"Glaxo Wellcome/GlaxoSmithKline","relationship":"Daly's former employer"},{"name":"Acadia Pharmaceuticals","relationship":"Daly's current board seat"},{"name":"Madrigal Pharmaceuticals","relationship":"Daly's current board seat"},{"name":"Cytokinetics","relationship":"Daly's current board seat"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-30T20:05:11.262Z","global_importance":12,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap biotech","eventGravity":"routine-board-appointment","issuerAuthored":true,"householdBrandBoost":"moderate (mid-cap biotech with named pharma partners)"}},"durationMs":4654,"modelName":"glm-5.3-flashx"}}